Bomalasky JS, Lluberas G, Schumacher HR Jr.
Monosodium urate crystals in the knee of patients with asymptomatic nontophaceous gout.
Arthritis Rheum 1986; 29: 1480-4.
Conagham PG, Day RO. Risk and benefits of drugs used in the
management and prevention of gout. Drug Safety 1994; 11: 252-8.
* Fam A. Gout in the elderly. Clinical prsentation and treatment.
Drugs&Aging 1998; 13: 229-43.
Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and
hyperuricemia. A long-term polpulation study. Am J Med 1967; 27-37.
* Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity.
Description and guidelines for prevention in patients with renal insufficiency. Am J Med
1984; 76: 47-56.
* Johnson RJ, Kivlinhn SD, Kim YG, Suga S, Fogo AB. Reappraisal of
the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease
, and renal disease. Am J Kidney Dis 1999; 33: 225-343.
Lin KC, Lin HY, Chou P. The interaction between uric acid level and
other risk factors on the development of gout among asymptomatic hyperuricemic men in a
prospective study. J Rheumatol 2000; 27: 1501-5.
McCarthy GM, Barthelemy CR, Veum JA, Wortman RL. Influrnce of
antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis
Rheum 1991; 34: 1489-94.
Pascual E, Batlle-Gualda E, Martinez A, Rosas J, Vele P. Synovial
fluid analysis for diagnosis of intercritical gout. Ann Intern Med 1999; 131: 756-9.
Perez Ruiz F, Calabozo Raluy M, Herrero Beites A, Ruiz Lucea E,
Alonso Ruiz A. Análisis de los métodos para clasificar la gota según la excreción
renal de ácido úrico. Rev Esp Reumatol 1998; 25: 335-9.
* Perez Ruiz F, Calabozo Raluy M, Alonso Ruiz A. Tratamiento de la
gota crónica. Una nueva aproximación a un antiguo problema. Rev Esp Reumatol 1999; 26:
21-5.
* Perez-Ruiz F, Gonzalez-Mielgo FJ, Herrero-Beites A. Optimisation
of the treatment of acute gout. Biodrugs 2000; 13: 415-423.
Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A,
García-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the
control of hyperuricemia. A pathogenic approach to the treatment of primary chornic gout.
Ann Rheum Dis 1998; 57: 245-9.
Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, Herrero-Beites A,
Ruiz-Lucea E,García-Erauskin G, Duruelo J,Alonso-Ruiz A. Treatment of chronic gout in
patients with renal function impairment. An open, randomized, actively controlled study. J
Clin Rheumatol 1999; 5: 49-54.
Perez-Ruiz F, Calabozo M, Herrero-Beites A, Garcia-Erauskin G,
Pijoan JI. Improvement of renal function in patients with chronic gout after proper
control of hyperuricemia and gouty bouts. Nephron 2000 (en prensa).
Puig JG, Mateos FA, Jimenez ML, Ramos TH. Renal excretion of
hypoxantine and xantine in primary gout. Am J Med 1988; 85: 533-7.
* Scott JT. Drug-induced gout. Bailliere´s Clin Rheumatol 1991; 5:
39-60.
* Seegmiller E. Human aberrations of purine metabolism and their
significance for Rheumatology. Ann Rheum Dis 1980; 39: 103-17.
* Sorensen LB. The pathogenesis of gout. Arc Intern Med 1962; 109:
55-66.
* Yü TF. Milestones in the treatmen of gout. Am J Med 1974; 56:
676-85.
